Single‐dose psilocybin superior to placebo for MDD in community setting
The Brown University Psychopharmacology Update · 2026-12 · 37 (12) · 3-3
DOI: 10.1002/pu.31520 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 14.11.2026.
Abstract (Originalsprache)
Major depressive disorder (MDD) affects about 300 million people worldwide. About one‐third of these have treatment‐resistant depression (TRD), commonly defined as a failure to respond to two antidepressants. Although these conditions represent a major public health problem, access to specialized treatments is limited.
Zitieren
APA
(2026). Single‐dose psilocybin superior to placebo for MDD in community setting. The Brown University Psychopharmacology Update, 37(12), 3-3. https://doi.org/10.1002/pu.31520
Vancouver
Single‐dose psilocybin superior to placebo for MDD in community setting. The Brown University Psychopharmacology Update. 2026;37(12):3-3. doi:10.1002/pu.31520
BibTeX
@article{euvimed2026,
title = {Single‐dose psilocybin superior to placebo for MDD in community setting},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {12},
pages = {3--3},
doi = {10.1002/pu.31520}
}
EUVIMED